We’re investigating treprostinil palmitil inhalation powder (TPIP), a dry powder formulation of treprostinil palmitil, as a potential therapy for rare pulmonary disorders, including pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. TPIP is an investigational product that has not been approved for any indication in any jurisdiction.